# MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP

> **NCT06361108** · PHASE1 · RECRUITING · sponsor: **Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Diabetic Peripheral Neuropathic Pain

## Interventions

- **DRUG:** YJ001 for Spray Use
- **DRUG:** Placebo of YJ001 for Spray Use

## Key facts

- **NCT ID:** NCT06361108
- **Lead sponsor:** Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-16
- **Primary completion:** 2025-12-20
- **Final completion:** 2026-06-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06361108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06361108, "MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06361108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*